Psychiatric symptoms and quality of life in Behçet patients;Behçet hastalarinda ruhsal belirtiler ve yaşam kalitesi

Anadolu Psikiyatri Dergisi

Volumn 7, Issue 3, 2006, Pages 133-139

  Uǧuz, Faruk ^a   Dursun, Recep ^b   Kaya, Nazmiye ^a   Çili, Ali Savaş ^a  

^a SELCUK UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

Beh disease; Psychiatric symptoms; Quality of life

Indexed keywords

ADULT; AGE; ARTICLE; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; BEHCET DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; EDUCATION; ENVIRONMENTAL FACTOR; FEMALE; HEALTH STATUS; HOSPITAL ADMISSION; HUMAN; HUMAN RELATION; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MENTAL DISEASE; OUTPATIENT DEPARTMENT; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SCORING SYSTEM; SEX DIFFERENCE; SYMPTOM; SYMPTOM CHECKLIST 90; UNIVERSITY HOSPITAL;

EID: 33748920059     PISSN: 13026631     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Behçet H. Uber rezidivierende aphthouse durch ein virus verurscahte Geschwuere am Mund, am Auge und an den Genitalien. Dermatol Monatsschr Wochenschr 1937; 105:1152-1157.
2. Schirmer M, Calamia KT, Direskeneli H. Ninth International Conference on Behçet's Disease, Seoul. Korea, May 27-29, 2000. J Rheumatol 2001; 28:636-639.
3. Calamia KT, Mazlumzadeh M. Behçet's disease. Bull Rheum Dis 2004; 53:1-8.
4. Marshall SE. Behçet's disease. Best Pract Res Clin Rheumatol 2004; 18:291-311.
5. Calikoglu E, Onder M, Cosar B, Candansayar S. Depression, anxiety levels and general psychological profile in Behçet's disease. Dermatology 2001; 203:238-240.
6. Karlidag R, Unal S, Evereklioglu C, Sipahi B, Er H, Yologlu S. Stressful life events, anxiety, depression and coping mechanisms in patients with Behçet's disease. J Eur Acad Dermatol Venereol 2003; 17:670-675.
7. Aslan SH, Soylu MB, Alparslan ZN, Ünal M. Behçet hastaliǧinda psikososyal etkenler ve ruhsal bulgular. Turk Psikiyatri Derg 1996; 7:215-221.
8. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335:1078-1080.
9. Derogatis LR. SCL-90 administration, scoring, and procedure manual for the Revised Version. Baltimore, Consulting Psychologists, 1977.
10. Daǧ I. Belirti tarama listesinin (SCL-90-R) üniversite öǧrencileri için geçerliǧi ve güvenirliǧi. Turk Psikiyatri Derg 1991; 2:5-12.
11. World Health Organization. WHOQOL, measuring quality of life. World Health Organization, WHO/MSA/MNH/PSF/, 1997.
12. Eser YS, Fidaner H, Fidaner C, Elbi H, Eser E, Göker E. Yaşam kalitesinin ölçülmesi, WHOQOL-100 ve WHOQOL-Brief. 3P Dergisi 1999; 7(Ek 2):5-13.
13. Beck AT, Ward CH, Mehdelson M, Mosk J, Erbaugh J. An inventory for measuring depresssion. Arch Gen Psychiatry 1961; 4:561-571.
14. Hisli N. Beck depresyon envanterinin üniversite öǧrencileri için geçerliǧi, güvenirliǧi. Psikoloji Dergisi 1989; 7:3-13.
15. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56:893-897.
16. Ulusoy M, Sahin NH, Erkmen H. Turkish version of the Beck Anxiety Inventory: psychometric properties. J Cogn Psychother 1998; 12:163-172.
17. Borson S. Behçet's disease as psychiatric disorder: A case report. Am J Psychiatry 1982; 139:1348-1349.
18. Sim M. Behçet's syndrome as a psychiatric disorder. Am J Psychiatry 1983:140:816.
19. Uhl V, Reus VI, Fromm JB. Psychiatric symptoms in Behçet's syndrome. Psychosomatics 1985; 26:547-549.
20. Epstein RS, Cumming NA, Sherwood EB, Bergsma DR. Psychiatric aspects of Behçet's syndrome. J Psychosom Res 1970; 14:161-72.
21. Koptagel-llal G, Tuncer O, Enbiyaoglu G, Bayramoglu Z. A psychosomatic investigation of Behçet's disease. Psychother Psychosom 1983; 40:263-271.
22. Akdeniz N, Esrefoglu M, Keles MS, Karakuzu A, Atasoy M. Serum interleukin-2, interleukin-6, tumor necrosis factor-alpha and nitric oxide levels in patients with Behçet's disease. Ann Acad Med Singapore 2004; 33:596-599.
23. Oztas MO, Onder M, Gurer MA, Bukan N, Sancak B. Serum interleukin 18 and tumor necrosis factor-alpha levels are increased Behçet's disease. Clin Exp Dermatol 2005; 30:61-63.
24. Duzgun N, Ayaslioglu E, Tutkak H, Aydintug OT. Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukine-1 receptor antagonist in Behçet's disease. Rheumatol Int 2005; 25:1-5.
25. Brebner K, Hayley S, Zacharko R, Merali Z, Anisman H. Synergistic effects of interleukin-1 β, interleukin-6, and tumor necrosis factor-α: central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology 2000; 22:566-580.
26. Tanriverdi N, Taskintuna I, Duru C, Ozdal P, OrtaC S, Firat E. Health-related quality of life in Behçet patients with ocular involvement. Jpn J Ophthalmol 2003; 47:85-92.
27. Bodur H, Borman P, Ozdemir Y, Atan C, Kural G. Quality of life satisfaction in patients with Behçet's disease: relationship with disease activity. Clin Rheumatol 2006; 25:329-333.